LSI

What does Medtronic prioritize when evaluating Medtech companies? According to Christopher Cleary, former Senior Vice President of Corporate Development at Medtronic, three key factors stand out: 1. Potential to Become the New Standard of Care: Medtronic is interested in technologies that could set a new standard in healthcare. They focus on whether the innovation can drive market adoption by being prioritized over existing standards of care. 2. Market Size and Growth Potential: Medtronic assesses how big the market is and what the potential growth could be, factoring in aspects like reimbursement. 3. Market Positioning and Entry Timing: Being the first to market with a product can be a significant advantage. Medtronic understands that the first market entrant, even with slightly inferior technology, can capture and maintain a substantial market share. They believe that the first player can hold onto almost two-thirds of the market share in a mature market with three equivalent products. Tune into the full video recording, “The Agony and Ecstasy of Doing Big Things in Medtech” to hear more from this group of panelists: • David Hochman (Moderator) — Orchestra BioMed • Howard Levin — Deerfield Catalyst • Christopher Cleary — Biomergence Capital

Agile Devices (LSI Europe ‘24 Innovator) is a medical device development company dedicated to the invention and realization of innovative steerable and deflectable catheter technologies designed to reduce procedure time, cost, and risk. With an initial focus on interventional radiology, Agile Devices' Angler Microcatheter features novel coaxial deflection technology which has the potential to make interventions cost-effective, faster, and safer. The company has made significant strides recently, achieving milestones such as: • Raised $1.6M of equity funding, led by Launchpad Venture Group • Expanded their advisory team including new Senior Medical Advisor, Dr. Thanh Nguyen from Boston Medical Center • Published the results of a 40-procedure Limited Market Evaluation (LME) across 9 US institutions in Endovascular Today, highlighting the early clinical experience with the FDA-cleared Angler® Steerable and Deflectable Microcatheter ( https://bit.ly/3WIVCcu ) • Strengthened their IP portfolio with new patent grants in multiple geographies, and continued to file new patent applications to further protect their technology We’re excited to announce that Co-Founder & CEO, Ben Merewitz has been selected to present Agile Devices at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Benjamin and learn more about Agile Devices

Strategic partnerships can be the key to accelerating your company’s growth, but forming these alliances requires more than just a good product. It’s about understanding your audience and delivering a message that resonates with their specific goals and priorities. In our latest LSI Europe ‘24 panel, "Telling the Right Story to the Right Person: Secrets to Forging Successful Partnerships With Strategics," we’ll delve into the nuances of how Medtech companies can effectively communicate their value to strategic partners. This session will focus on tailoring your narrative to fit the needs of potential partners, aligning your objectives, and building long-lasting, mutually beneficial relationships. We’ll hear perspectives from: • Ken Nelson (Moderator) — MedTech Advantage Fund • Elizabeth Hoff — SOMAVAC® Medical Solutions, Inc. • Bhavesh Barot — GE HealthCare • Liam J. Burns — Qaelon Medical Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

GlucoModicum Ltd (LSI Europe ‘24 Innovator) is a company founded and headquartered in Finland that's transforming glucose monitoring with proprietary needle-free magnetohydrodynamic (MHD) technology. Annual diabetes-related healthcare costs are about $1 trillion globally, with more than 1.31 billion people projected to have diabetes by 2050. There is a significant need for better, cost-effective, and accessible diabetes management. To address the diabetes epidemic, it is recommended and essential to monitor glucose levels in order to intervene early, empowering people to make healthier lifestyle choices. Talisman, GlucoModicum’s needle-free continuous glucose monitor (CGM) uses MHD technology to extract interstitial fluid through the skin without the use of needles. By integrating ultra-sensitive and low-cost biosensors, Talisman enables continuous, painless, and accurate monitoring of glucose levels with enormous potential to help people with or at risk of developing diabetes to lead healthier lives. The company has made significant strides recently, achieving milestones such as: • Completed a significant funding round backed by a consortium of international investors and family offices. Using this funding, the company continues to make clinical and commercial progress as it prepares for product launch. • Data from an ongoing Clinical Performance Study of Talisman confirms a strong correlation to blood glucose values (currently, N>100 individual tests). • The GlucoModicum team continues to expand, currently consisting of approximately 50 highly talented individuals from across 16 different countries. We’re excited to announce that CEO, Jokke Mäki has been selected to present GlucoModicum at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jokke and learn more about GlucoModicum.

TVM Capital Life Science is a leading transatlantic Venture Capital firm that’s set to join us at LSI Europe ‘24 this September in Portugal. TVM Capital Life Science, with approximately $900 million under management, invests in therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform the standard of care. They pursue a unique, two-pronged strategy, investing in differentiated commercial-stage medical technologies and late clinical-stage therapeutics, as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with Eli Lilly and Company. TVM Capital Life Science Portfolio includes companies like: • Access Vascular, Inc. (#LSIAlumni - James Biggins) • Egg Medical (LSI Alumni - Robert Wilson) • Vektor Medical, Inc. (LSI Alumni - Robert J. Krummen) • Kent Imaging (LSI Alumni - Pierre Lemire) • among others We’re excited to welcome TVM Capital Life Science Managing Partner, Dr. Luc Marengere to LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Dr. Marengere will also be participating in the panel, “Building Syndicates of Cross-Border Investors in Medtech Companies” on September 17th at 3:45 pm in Track 1.

Are the days of single-product Medtech companies going public over? Duke Rohlen, CEO of Ajax Health, argues that the era of single-product Medtech companies thriving in public markets is over. The current investment climate demands more than just potential; there’s an increasing focus on profitability. Rohlen explains that single-product companies often struggle because they lack the resources to diversify their portfolios. They invest heavily in sales and marketing, but without a broader range of products, they can't maintain the acquisition premium that once made them attractive to buyers. To succeed in today's market, Rohlen advises Medtech companies to focus on diversification and ensure there’s a clear path to profitability. Without these, companies may find it difficult to sustain value in the public markets or attract long-term investors. Catch the full panel, “Medtech Buyouts by Private Equity” now available on our website and YouTube channel. Featured Panelists: • David Uffer (Moderator) — Trinity Life Sciences • Antonio Sánchez-Cordero — ARCHIMED • Duke Rohlen — Ajax Health • Erich Wolff — Partners Group You can hear more from Duke Rohlen, CEO and Managing Director of Ajax Health, at LSI Europe '24 where he will be giving a Keynote Presentation based on his recently published thesis, "The Middle Path to Innovation," published in the Harvard Business Review. He will discuss strategies for developing high-growth products in slow-growth companies and present the growth driver model—a framework that partners corporations with external investors to identify and develop innovation opportunities, drawing on corporate resources and talent and externally recruited entrepreneurs.

With just 3 weeks to go before LSI Europe ‘24, we're announcing our last call for presenter applications. Limited spaces are still available before we reach capacity. Nearly all presenting companies have been selected, and we are seeing an unprecedented investor turnout. This year, we will host more top funds than ever before, creating the highest investor-to-attendee ratio in our history. If you’re looking to connect with industry-leading investors—venture capital, private equity, angel groups, accelerators, and more—this is the place to do it. You can view a comprehensive list of confirmed investors on our website. Interested in speaking, presenting, or exhibiting at LSI Europe '24? Join hundreds of global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply today while space is still available.

We're kicking off day one of LSI Europe '24 with Dr. Todd Brinton, MD, Corporate Vice President, Advanced Technology, and Chief Scientific Officer at Edwards Lifesciences, as our opening Keynote Speaker. A champion of cardiovascular innovation and a practicing clinical cardiologist, Dr. Brinton has deep ties to the Medtech community as a founder, board member, and advisor to several startup companies, including his role as physician founder, board member, and chief medical officer of Shockwave Medical, Inc. (SWAV). Before joining Edwards, Dr. Brinton was a clinical professor of medicine (cardiology) and adjunct professor of bioengineering at the Stanford University School of Medicine where he also served as the fellowship director at the Byers Center for Biodesign from 2006 to 2019, mentoring numerous teams in developing new technologies. This Keynote will take place at 9:10 am on September 17th and be moderated by Dr. Josh Makower, Co-Founder and Director of the Stanford Byers Center for Biodesign. Interested in speaking, presenting, or exhibiting at LSI Europe '24? Join hundreds of global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply today while space is still available.

FaceHeart’s vision is to leverage its patented rPPG and AI solution to enhance the quality and accessibility of healthcare, contributing to the acceleration of the digital health industry. FaceHeart offers non-invasive, seamless and contactless, video-based vital signs solution, FaceHeart Vitals™, that measures all the key vital signs, including Heart Rate, Blood Pressure, SpO2 and Respiration Rate as well as health indicators with a simple 45-second selfie video. As a Software as a Medical Device (SaMD), FH Vitals SDK is the only FDA-cleared rPPG technology that transforms your everyday devices with cameras into health monitors, enabling more affordable and high-quality healthcare anytime and anywhere. The company has made significant strides recently, achieving milestones such as: • Received FDA 510(k) clearance (K223622) for its contactless vital signs solution, FH Vitals SDK (Heart Rate). (Sept 2023) • Currently working on additional clearance for other vitals • Has a strong portfolio of patents in both the US and Taiwan, with many granted and more pending. • Collaborated with numerous hospitals and received over 200M clinical datasets from over 6000 testers, enabling its solution to achieve medical-grade accuracy. (June 2024) We’re excited to announce that CEO, Jerry S Chang has been selected to present FaceHeart at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jerry and learn more about FaceHeart.

Hot off the press! The latest edition of The Memo, featuring Virpi Muhonen, Co-Founder & CEO of Askel Healthcare Ltd is out now! Here’s a preview of this week’s edition of our weekly newsletter, The Memo: Led by Co-Founder & CEO Virpi Muhonen, Askel Healthcare is transforming knee cartilage repair with their COPLA® Cartilage Implant. Backed by promising clinical trial results and FDA Breakthrough Device Designation, the company is advancing toward market authorization, aiming to set a new global standard in orthopedic care. The Current Landscape Cartilage lesions, especially in the knee, present a significant clinical challenge. These injuries, if left untreated, often lead to the progressive development of osteoarthritis—a debilitating degenerative joint disease that severely impacts a patient’s quality of life. The current standard of care for treating these lesions is fraught with limitations, often failing to deliver the long-term outcomes that patients need. "Unfortunately, all these first-line surgical treatments have poor long-term outcomes," explains Muhonen. "Patients who suffer a traumatic knee injury, often undergo procedures like microfracturing, cartilage grafting, or simple cleaning of the damaged area, but these solutions are not enough. They provide temporary relief, but the underlying issue remains unresolved." In the United States alone, approximately 750,000 knee cartilage repair operations are performed annually. Most of these—around 600,000—are first-line treatments such as microfracturing and cleaning procedures. Despite the high volume of surgeries, the outcomes are often disappointing. Patients are frequently left with persistent pain, limited mobility, and a significant risk of requiring additional surgeries down the line. Inside the Innovation Askel Healthcare’s innovative solution, the COPLA® Cartilage Implant, is designed to address the fundamental issues that plague current treatment options, offering a more effective and patient-friendly alternative for cartilage repair. "The COPLA Cartilage Implant is made of biodegradable polymers, creating a three-dimensional environment that allows cartilage tissue to heal," explains Muhonen. "What sets COPLA apart is its ability to enable immediate weight-bearing post-surgery. Patients can move freely without any weight-bearing restrictions, which is not only convenient but crucial for the healing process." Continue Reading: https://lnkd.in/gVMhgARb